- Home
- NAMS
as 09-05-2025 4:00pm EST
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | 2.7B | IPO Year: | N/A |
| Target Price: | $41.40 | AVG Volume (30 days): | 872.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.06 - $27.29 | Next Earning Date: | 08-06-2025 |
| Revenue: | $64,006,000 | Revenue Growth: | 762.15% |
| Revenue Growth (this year): | -34.14% | Revenue Growth (next year): | -17.84% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 months ago
Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14%
GlobeNewswire
3 months ago
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
GlobeNewswire
3 months ago
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
GlobeNewswire
3 months ago
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
GlobeNewswire
4 months ago
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
Simply Wall St.
4 months ago
NewAmsterdam Pharma First Quarter 2025 Earnings: US$0.34 loss per share (vs US$1.06 loss in 1Q 2024)
GlobeNewswire
4 months ago
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GlobeNewswire
4 months ago
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.